文献速递认知障碍与痴呆

米诺环素两种剂量与安慰剂治疗轻度阿尔茨海默病的随机临床试验

Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2020-01-01

这项双盲随机试验纳入554例轻度AD患者,比较米诺环素400 mg/d、200 mg/d与安慰剂治疗24个月的效果。结果显示米诺环素未延缓认知或功能衰退,且400 mg/d耐受性差,因胃肠道、皮肤及头晕等不良反应导致完成率低。

要点

  • 米诺环素未延缓轻度AD患者24个月的认知或功能衰退。
  • 400 mg/d米诺环素耐受性差,完成率仅28.8%,主要因胃肠道和皮肤不良反应。
  • 200 mg/d组与安慰剂组完成率相似,但认知功能下降程度无显著差异。

核心结论

  • 米诺环素未延缓轻度AD患者2年内的认知或功能衰退。
  • 400 mg/d米诺环素在该人群中耐受性差。

研究设计与样本

  • 双盲随机临床试验,2014年5月23日至2016年4月14日在英格兰和苏格兰32家NHS记忆门诊招募。
  • 从886例筛查患者中随机分配554例轻度AD患者(sMMSE≥24),按1:1:1半因子设计接受米诺环素400 mg/d、200 mg/d或安慰剂治疗24个月。
  • 主要结局为sMMSE和BADLS评分下降,采用意向性治疗重复测量回归分析。

主要发现

  • 544例 eligible 参与者(241女,303男),平均年龄74.3岁(SD 8.2),平均sMMSE 26.4(SD 1.9)。
  • 400 mg组完成治疗比例28.8%(53/184),低于200 mg组61.9%(112/181)和安慰剂组63.7%(114/179),P < .001。
  • 24个月时sMMSE下降在米诺环素联合组与安慰剂组相似(4.1 vs 4.3分),联合组平均sMMSE高0.1分(95% CI -1.1 to 1.2;P = .90)。
  • BADLS恶化在各组相似:400 mg组5.7,200 mg组6.6,安慰剂组6.2;米诺环素 vs 安慰剂治疗效应-0.53(95% CI -2.4 to 1.3;P = .57)。

关键数值与推荐

  • 认知衰退:24个月sMMSE下降米诺环素联合组4.1分 vs 安慰剂组4.3分,组间差异0.1分(95% CI -1.1 to 1.2;P = .90)。
  • 功能衰退:BADLS恶化米诺环素 vs 安慰剂治疗效应-0.53(95% CI -2.4 to 1.3;P = .57)。
  • 耐受性:400 mg组因胃肠道症状42例、皮肤不良反应10例、头晕14例导致停药,相应P值分别为< .001、.02、.01。

临床怎么用

  • 米诺环素不推荐用于轻度AD的疾病修饰治疗。
  • 若考虑使用米诺环素,400 mg/d剂量因耐受性差不宜采用。

局限性

  • 400 mg组评估率较低(24个月sMMSE评估率68.4%),可能影响结果解释。
  • 完成治疗比例在400 mg组显著偏低,脱落主要因不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of β-amyloid in vitro and in animal models of AD, and is a credible repurposed treatment candidate. OBJECTIVE: To determine whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild AD. DESIGN, SETTING, AND PARTICIPANTS: Participants were recruited into a double-blind randomized clinical trial from May 23, 2014, to April 14, 2016, with 24 months of treatment and follow-up. This multicenter study in England and Scotland involved 32 National Health Service memory clinics within secondary specialist services for people with dementia. From 886 screened patients, 554 patients with a diagnosis of mild AD (Standardised Mini-Mental State Examination [sMMSE] score ≥24) were randomized. INTERVENTIONS: Participants were randomly allocated 1:1:1 in a semifactorial design to receive minocycline (400 mg/d or 200 mg/d) or placebo for 24 months. MAIN OUTCOMES AND MEASURES: Primary outcome measures were decrease in sMMSE score and Bristol Activities of Daily Living Scale (BADLS), analyzed by intention-to-treat repeated-measures regression. RESULTS: Of 544 eligible participants (241 women and 303 men), the mean (SD) age was 74.3 (8.2) years, and the mean (SD) sMMSE score was 26.4 (1.9). Fewer participants completed 400-mg minocycline hydrochloride treatment (28.8% [53 of 184]) than 200-mg minocycline treatment (61.9% [112 of 181]) or placebo (63.7% [114 of 179]; P < .001), mainly because of gastrointestinal symptoms (42 in the 400-mg group, 15 in the 200-mg group, and 10 in the placebo group; P < .001), dermatologic adverse effects (10 in the 400-mg group, 5 in the 200-mg group, and 1 in the placebo group; P = .02), and dizziness (14 in the 400-mg group, 3 in the 200-mg group, and 1 in the placebo group; P = .01). Assessment rates were lower in the 400-mg group: 68.4% (119 of 174 expected) for sMMSE at 24 months compared with 81.8% (144 of 176) for the 200-mg group and 83.8% (140 of 167) for the placebo group. Decrease in sMMSE scores over 24 months in the combined minocycline group was similar to that in the placebo group (4.1 vs 4.3 points). The combined minocycline group had mean sMMSE scores 0.1 points higher than the placebo group (95% CI, -1.1 to 1.2; P = .90). The decrease in mean sMMSE scores was less in the 400-mg group than in the 200-mg group (3.3 vs 4.7 points; treatment effect = 1.2; 95% CI, -0.1 to 2.5; P = .08). Worsening of BADLS scores over 24 months was similar in all groups: 5.7 in the 400-mg group, 6.6 in the 200-mg group, and 6.2 in the placebo groups (treatment effect for minocycline vs placebo = -0.53; 95% CI, -2.4 to 1.3; P = .57; treatment effect for 400 mg vs 200 mg of minocycline = -0.31; 95% CI, -0.2 to 1.8; P = .77). Results were similar in different patient subgroups and in sensitivity analyses adjusting for missing data. CONCLUSIONS AND RELEVANCE: Minocycline did not delay the progress of cognitive or functional impairment in people with mild AD during a 2-year period. This study also found that 400 mg of minocycline is poorly tolerated in this population. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN16105064.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Howard R, Zubko O, Bradley R, et al. Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 31738372. doi:10.1001/jamaneurol.2019.3762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。